This suggests that NF1 patients (as opposed to sporadic MPNST) would have an advantage in fighting against cancer, but this idea does not translate in the clinic, meaning that other mechanisms may counterbalance. This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.